The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ
Open accessAbstract
Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases owing to their immunosuppressive properties. In this study, we aimed to identify the effect of interferon (IFN)-γ priming on immunomodulation by MSCs and elucidate the possible mechanism underlying their properties for the clinical treatment of allogeneic conflicts. Infusion of MSCs primed with IFN-γ significantly reduced the symptoms of graft-versus-host disease (GVHD) in NOD-SCID mice, thereby increasing survival rate when compared with naïve MSC-infused mice. However, infusion of IFN-γ-primed MSCs in which indoleamine 2,3-dioxygenase (IDO) was downregulated did not elicit this effect. The IDO gene was expressed in MSCs via the IFN-γ-Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) pathway, and the infusion of IDO-over-expressing MSCs increased survival rate in an in vivo GVHD model, similar to infusion of IFN-γ-primed MSCs. These data indicate that IFN-γ production by activated T-cells is correlated with the induction of IDO expression in MSCs via the IFN-γ-JAK-STAT1 pathway, which in turn results in the suppression of T-cell proliferation. Our findings also suggest that cell therapy based on MSCs primed with IFN-γ can be used for the clinical treatment of allogeneic conflicts, including GVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells
Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., & Verfaillie, C. M. (2001) · Blood · doi:10.1182/blood.v98.9.2615 · Cited by 1,185
RetractedMultilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956
Caplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues
Prockop, D. J. (1997) · Science · doi:10.1126/science.276.5309.71 · Cited by 4,629
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Mesenchymal stem cells: clinical applications and biological characterization
Barry, F. P., & Murphy, J. M. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.11.001 · Cited by 1,665
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00110-3 · Cited by 1,623
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Mechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008) · Blood · doi:10.1182/blood-2007-02-074997 · Cited by 1,146
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.-U., Dlugosz, A., Szakos, A., Hassan, Z., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000214462.63943.14 · Cited by 1,142
Koç, O. N., Gerson, S. L., Cooper, B. W., Dyhouse, S. M., Haynesworth, S. E., Caplan, A. I., & Lazarus, H. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.307 · Cited by 1,119
Baksh, D., Song, L., & Tuan, R. S. (2004) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2004.tb00320.x · Cited by 1,105
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells
Sato, K., Ozaki, K., Oh, I., Meguro, A., Hatanaka, K., Nagai, T., Muroi, K., & Ozawa, K. (2007) · Blood · doi:10.1182/blood-2006-02-002246 · Cited by 954
Sekiya, I., Larson, B. L., Smith, J. R., Pochampally, R., Cui, J., & Prockop, D. J. (2002) · STEM CELLS · doi:10.1634/stemcells.20-6-530 · Cited by 943
Augello, A., Tasso, R., Negrini, S. M., Amateis, A., Indiveri, F., Cancedda, R., & Pennesi, G. (2005) · European Journal of Immunology · doi:10.1002/eji.200425405 · Cited by 696
Matrix Cells from Wharton's Jelly Form Neurons and Glia
Mitchell, K. E., Weiss, M. L., Mitchell, B. M., Martin, P., Davis, D., Morales, L., Helwig, B., Beerenstrauch, M., Abou-Easa, K., Hildreth, T., et al. (2003) · STEM CELLS · doi:10.1634/stemcells.21-1-50 · Cited by 634
Sotiropoulou, P. A., Perez, S. A., Salagianni, M., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0331 · Cited by 627
Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03422.x · Cited by 596
IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200738129 · Cited by 581
Munn, D. H., Sharma, M. D., & Mellor, A. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4100 · Cited by 457
Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy
Phinney, D. G. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24166 · Cited by 434
Chan, J. L., Tang, K. C., Patel, A. P., Bonilla, L. M., Pierobon, N., Ponzio, N. M., & Rameshwar, P. (2006) · Blood · doi:10.1182/blood-2006-01-0057 · Cited by 418
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
English, K., French, A., & Wood, K. J. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.009 · Cited by 303
Opitz, C. A., Litzenburger, U. M., Lutz, C., Lanz, T. V., Tritschler, I., Köppel, A., Tolosa, E., Hoberg, M., Anderl, J., Aicher, W. K., et al. (2009) · Stem Cells · doi:10.1002/stem.7 · Cited by 299
Müller, M., Carter, S., Hofer, M. J., & Campbell, I. L. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01089.x · Cited by 293
Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
Soleymaninejadian, E., Pramanik, K., & Samadian, E. (2012) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01069.x · Cited by 239
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells.
Vogel, W., Grünebach, F., Messam, C. A., Kanz, L., Brugger, W., & Bühring, H. (2003) · PubMed · Cited by 224
Biochemical Heterogeneity of Mesenchymal Stem Cell Populations: Clues to their Therapeutic Efficacy
Phinney, D. G. (2007) · Cell Cycle · doi:10.4161/cc.6.23.5095 · Cited by 211
Mesenchymal stem cells in immunoregulation
Chen, X., Armstrong, M. A., & Li, G. (2006) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2006.01458.x · Cited by 206
Waterman, R. S., Henkle, S. L., & Betancourt, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045590 · Cited by 197
Mesenchymal stem cells from cryopreserved human umbilical cord blood
Lee, M. W., Choi, J., Yang, M. S., Moon, Y. J., Park, J. S., Kim, H. C., & Kim, Y. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.206 · Cited by 157
Self-citationMesenchymal stem cells and autoimmune diseases
Dazzi, F., & Krampera, M. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.01.002 · Cited by 143
Ringdén, O. T. H., Remberger, M., Svahn, B., Barkholt, L., Mattsson, J., ASCHAN, J., Blanc, K. L., Gustafsson, B. M., Hassan, Z., Omazic, B., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000181457.43146.36 · Cited by 67
Fallarino, F., & Grohmann, U. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795656027 · Cited by 60
Wang, H., Asavaroengchai, W., Yeap, B. Y., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168419 · Cited by 56
Advances in the treatment of acute graft‐versus‐host disease
Qian, L., Wu, Z., & Shen, J. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12093 · Cited by 45
Asavaroengchai, W., Wang, H., Wang, S., Wang, L., Bronson, R. T., Sykes, M., & Yang, Y. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.09.014 · Cited by 42
Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases
Tan, P., & Bharath, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903018940 · Cited by 31
Stec, M., Baran, J., Baj‐Krzyworzeka, M., Węglarczyk, K., Goździk, J., Siedlar, M., & Zembala, M. (2012) · PubMed · Cited by 17
Cited by
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential
Song, N., Scholtemeijer, M., & Shah, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.009 · Cited by 948
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning
Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02837 · Cited by 572
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., Vega, B., Schneider, J., & Vizoso, F. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03600-0 · Cited by 313
Torres Crigna, A., Uhlig, S., Elvers-Hornung, S., Klüter, H., & Bieback, K. (2020) · Cells · doi:10.3390/cells9112419 · Cited by 46
Metadata
- Authors
- Kim, D. S., Jang, I. K., Lee, M. W., Ko, Y. J., Lee, D.-H., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 28
- Pages
- 261-273
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2783211174
- Cited by
- 287
- References
- 45
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.